Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.

Study summary:

This study will evaluate if TLI-ATG conditioning followed by allogeneic hematpoietic cell transplant (HCT), which has provided excellent overall survival for patients with relapsed lymphoma after failed autologous HCT, provides a similar benefit in the setting of elderly patients with hematologic malignancies.


INCLUSION CRITERIA: - Any patient with one of the following hematolymphoid malignancies or syndromes in whom allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease categories include: - Indolent advanced stage non-Hodgkin lymphomas - Mantle cell lymphoma - Chronic lymphocytic leukemia - Hodgkin disease (Hodgkin's lymphoma) - Acute leukemias in complete remission - Aplastic anemia - Paroxysmal nocturnal hemoglobinuria - Myelodysplastic or myeloproliferative syndromes. - Other selected malignancies/disorders may also be considered but must be approved by the transplant team and the Principal Investigator. - Age > 50 years, or if < 50 years of age, considered to be at high risk for regimen-related toxicity associated with conventional myeloablative transplants due to pre-existing medical conditions or prior therapy. - A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is available. Potential participants with one antigen mismatched donors can be considered but only after discussion with the transplant team and the Principal Investigator. - Participant must be competent to give consent. EXCLUSION CRITERIA: - Progressive hematolymphoid malignancies despite conventional therapies, or acute leukemias not in complete remission. - Uncontrolled central nervous system (CNS) involvement with disease - Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment - Pregnant - Cardiac ejection fraction < 30% - Uncontrolled cardiac failure - Pulmonary diffusing capacity (DLCO) < 40% predicted - Elevation of bilirubin to > 3 mg/dL - Transaminases > 4 x the upper limit of normal - Creatinine clearance < 50 cc/min (24-hour urine collection) - Karnofsky performance score < 60% - Poorly controlled hypertension on multiple antihypertensives - Documented fungal disease that is progressive despite treatment - HIV-positive. Other viral infections, ie, Hepatitis B- and C- positive, evaluated on a case-by-case basis - Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or Principal Investigator would place the patient at unacceptable risk from this regimen.



Primary Contact:

Principal Investigator
Robert Lowsky
Stanford University

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.